Cardiology Review® OnlineNovember 2008
Volume 25
Issue 11

Cardiology Review

In the October 2008 issue of , we incorrectly stated in our Product Spotlight section that “Boston Scientific received approval in July 2008 for their Xience™ V Everolimus-Eluting Coronary Stent for the treatment of coronary artery disease.” It should have said that Abbott Vascular received this approval and will market the Xience V. Abbott supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS™ Everolimus-Eluting Coronary Stent System. We regret the mistake.

For more on stents, please look for our Stent Round Table in December.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.